학술논문
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
Document Type
article
Author
Mengxing Li; Suryavathi Viswanadhapalli; Bindu Santhamma; Uday P. Pratap; Yiliao Luo; Junhao Liu; Kristin A. Altwegg; Weiwei Tang; Zexuan Liu; Xiaonan Li; Behnam Ebrahimi; Hui Yan; Yi Zou; Swapna Konda; Gangadhara R. Sareddy; Zhenming Xu; Yidong Chen; Manjeet K. Rao; Andrew J. Brenner; Virginia G. Kaklamani; Rajeshwar R. Tekmal; Gulzar Ahmed; Ganesh V. Raj; Klaus J. Nickisch; Hareesh B. Nair; Ratna K. Vadlamudi
Source
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Subject
Language
English
ISSN
2399-3642
Abstract
Li, Viswanadhapalli et al utilized multiple in vitro, ex vivo and in vivo models of TNBC to investigate LIFR inhibition. The authors reported that HDAC inhibition in TNBC cells led to an increase of LIFR expression and over activation of the downstream signaling elements (e.g., STAT3, mTOR, AKT), enhancing the aggressive potential of TNBC cells, and an LIFR inhibitor, EC359, synergistically enhanced the efficacy of HADC inhibitors in suppressing TNBC in vitro and in vivo.